Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22020117 | 0.80 | GAA (0.46) | CYP1A2GAANPSR1USP2KDM4E | |
| SCHEMBL21963218 | 0.80 | GAA (0.46) | CYP1A2GAANPSR1USP2KDM4E | |
| SCHEMBL22019956 | 0.79 | CYP1A2 (0.47) | CYP1A2GAANPSR1USP2KDM4E | |
| SCHEMBL22019866 | 0.79 | GAA (0.44) | CYP1A2GAANPSR1USP2KDM4E | |
| SCHEMBL22019717 | 0.77 | KDM4E (0.36) | KDM4EACHEMEN1KMT2A | |
| SCHEMBL31651305 | 0.73 | CYP1A2 (0.39) | CYP1A2GAANPSR1USP2KDM4E | |
| SCHEMBL22019942 | 0.72 | ACHE (0.55) | CYP1A2KDM4EACHEMEN1TSHR | |
| SCHEMBL30120892 | 0.72 | ACHE (0.55) | CYP1A2KDM4EACHEMEN1TSHR | |
| SCHEMBL22020361 | 0.71 | USP2 (0.40) | CYP1A2GAANPSR1USP2KDM4E | |
| SCHEMBL24478599 | 0.71 | GAA (0.34) | CYP1A2GAAKDM4EMAPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CYP1A2 1790/4885GAA 1444/4885NPSR1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.